HIV-related morbidity and mortality in patients starting protease inhibitors in very and advanced HIV disease (CD4 count of <50 cells/μL): An analysis of 338 clinical events from a randomized clinical trial

HIV Medicine

Volumn 3, Issue 2, 2002, Pages 75-84

  Floridia, M ^a   Fragola, V ^a   Galluzzo, C M ^a   Giannini, G ^a   Pirillo, M F ^a   Andreotti, M ^a   Tomino, C ^a   Vella, S ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

AIDS; CD4; Clinical events; HIV progression

Indexed keywords

CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; HIV PROTEASE INHIBITORS; HUMANS;

EID: 0036261455     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2002.00104.x     Document Type: Article

References (39)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
3. AIDS across Europe, 1994-98: EuroSIDA Study
4. The effect of HAART on retinal and extraocular cytomegalovirus infection in patients with AIDS in Europe
5. Effect of highly active antiretroviral therapy on the incidence of HIV-related cytomegalovirus retinitis and retinal detachment
6. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy
7. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects
8. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy
9. Decreasing incidence of non-Hodgkin lymphoma (NHL) in the era of HAART. The EuroSIDA study
10. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center
11. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)
12. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
13. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy
14. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy
15. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents
16. Evolving characteristics of AIDS-related lymphoma
17. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
18. Opportunistic infections occurring during highly active antiretroviral treatment
19. Opportunistic infections shortly after beginning highly active antiretroviral therapy
20. Opportunistic infections: What's new?
21. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection
22. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV disease progression: Results from the EuroSIDA study
23. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
24. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneunocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo Estudio del SIDA 04/98
25. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: The changes in opportunistic prophylaxis study
26. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
27. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: Secondary prophylaxis
28. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection
29. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
30. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
31. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
32. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study
33. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy
34. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
35. The changing face of AIDS-related opportunism: Cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review
36. Immune mediated 'HAART' attack during treatment for tuberculosis. Highly active antiretroviral therapy
37. Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy
38. 3 despite effective HAART
39. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy